Project Grant HT94252510481
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$2.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This $590,400 federal Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports research to develop an epigenetic innate immune memory biomarker for Gulf War Illness. The award to The Trustees of Princeton University covers the period from July 1, 2025 to June 30, 2028. The research aims to investigate an "Epigenetic Innate Immune Memory Hypothesis for Gulf War Illness" and develop a...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $713,277 to Boston University Medical Campus to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness. The award will support the project from September 1, 2024 through August 31, 2027. As part of this...
The Department of the Army Medical Command awarded a $999,975.63 Project Grant titled "MOLECULAR MECHANISMS OF APOE4 VULNERABILITY TO ALZHEIMER'S DISEASE AND IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS" to the Icahn School of Medicine at Mount Sinai (ISMMS) on April 1, 2025. This grant, funded under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research initiatives focused on transforming healthcare for military service members and...
This $949,181 federal Project Grant award was provided by the U.S. Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund research by the Icahn School of Medicine at Mount Sinai to investigate the association between cortical lesions and physical/cognitive disability in multiple sclerosis using novel, clinically feasible MRI methods. The research aims to advance the understanding and treatment of multiple sclerosis, a...
This Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), provides $1,704,652.00 to Trustees of Boston University (Boston University Medical Campus) to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness (GWI). The award period runs from September 1, 2024 to August...
The Defense Health Agency awarded a $1.687 million Project Grant to the Icahn School of Medicine at Mount Sinai under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of May 1, 2023 to April 30, 2027. The grant will fund research investigating the role of medial amygdala circuits in mediating the effects of diet on post-traumatic behavioral and metabolic complications. Through basic, applied, and advanced biomedical research, this project aims to...
This $1,994,937 federal Project Grant award, funded by the U.S. Department of Defense through the Military Medical Research and Development program (CFDA 12.420), is supporting research to confirm the effectiveness of acupuncture in treating the symptoms of Gulf War Illness. The grant recipient, Beth Israel Deaconess Medical Center, Inc. (Bidmc), a prominent academic medical center in Boston, will conduct this research project over a 4-year period from August 2024 to July 2028. Bidmc has...
The U.S. Department of Defense's Defense Health Agency awarded a $319,204 Project Grant to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on "Advanced Brain Age Modeling in Multiple Sclerosis: Toward a Prognostic Biomarker for Personalized Medicine." The award, which runs from August 15, 2024, to August 14, 2026, is part of the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research initiatives aimed at...
This $634,256 Cooperative Agreement award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (HJF) to identify metabolic biomarkers associated with Gulf War exposures and Gulf War Illness. The three-year project, commencing on September 15, 2023, will leverage the DoD Serum Repository to advance the understanding of the biological...
This federal Project Grant award of $505,270.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Icahn School of Medicine at Mount Sinai to investigate the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathway in lethal prostate cancer. The goal is to develop a novel therapeutic strategy. The award has a performance period from September 30, 2025 to September 29, 2027. As a prominent...